Salesforce stock surged 22% this week after beating Q2 2027 earnings expectations with $11.35B in revenue versus $11.32B expected, and posting $4.29 diluted EPS versus $3.27 anticipated. The company raised its fiscal 2027 revenue guidance to $46.1-$46.4B and EPS guidance to $10.21-$10.25, prompting analysts to raise price targets. At 12.1x operating cash flow versus its five-year average of 18.3x, the stock is considered undervalued.

Kirby McInerney LLP is investigating Jefferies Financial Group for potential securities law violations related to alleged misleading disclosures about the company's exposure to First Brands Group, a bankrupt auto-parts supplier, through its asset-management unit Point Bonita Capital. The SEC is reportedly investigating claims that Jefferies misled investors, with Point Bonita funds owed approximately $715 million from companies that purchased First Brands' parts. Jefferies disclosed a $30 million loss tied to First Brands' collapse, and the stock declined 9% on the news.

Historical data suggests investors should wait until mid-2027 or later before buying SpaceX stock, despite the company's recent IPO and operational achievements. Large IPOs typically underperform their market index by 4% over three years, and SpaceX's high P/S ratio of 76 (versus tech sector average of 9) indicates overvaluation. Additionally, accelerating capital expenditures in AI investments raise concerns about future returns.

Dyne Therapeutics, a clinical-stage neuromuscular disease company, announced a $300 million underwritten public offering of common stock with a 30-day option for underwriters to purchase an additional $45 million. Morgan Stanley, Jefferies, Evercore ISI, LifeSci Capital, and Raymond James are serving as joint book-running managers. The offering is subject to market conditions and SEC approval.

SpaceX stock, which opened at $150 over a month ago, is now trading below that level. Based on 26 years of historical IPO data, large IPOs typically gain only 3.5-4% in their first year, suggesting SpaceX shares could reach around $156 within 11 months. The company faces headwinds including unprofitability, massive capital expenditures ($27 billion in 2025), risky bets on Starship rocket technology, and an unproven orbital AI data center plan. Analysts' price targets range from $300-$800, but historical trends suggest more modest gains.

Law firm Bragar Eagel & Squire is investigating Jefferies Financial Group for potential securities violations related to its Point Bonita Capital fund's $715 million exposure to bankrupt auto supplier First Brands. The investigation follows SEC inquiry into whether Jefferies adequately disclosed risks to investors. Jefferies stock declined significantly following multiple negative disclosures about the First Brands collapse and subsequent weak earnings reports.

The Portnoy Law Firm has initiated a securities fraud investigation into Jefferies Financial Group following significant losses tied to auto supplier First Brands' bankruptcy. Jefferies' Point Bonita Capital fund faced approximately $715 million in exposure to First Brands. The company took a $30 million loss and disclosed declining asset management fees and investment returns in Q2 2026 results, leading to multiple stock price declines totaling over 25% across several disclosure dates.

Block & Leviton is investigating Unicycive Therapeutics for potential securities law violations related to false or misleading statements about FDA review of its OLC New Drug Application. The company received a second Complete Response Letter on June 30, 2026, citing manufacturing deficiencies, which led to a stock price decline. Investors who have suffered losses are encouraged to contact the firm.

Block & Leviton is investigating Alignment Healthcare, Inc. (ALHC) for potential securities law violations following allegations that a former executive filed a whistleblower lawsuit claiming the company manipulated finances to boost stock price and executive compensation. The stock fell approximately 16.72% following the report. The firm is also investigating Jefferies Financial Group and Unicycive Therapeutics for similar violations.

Vertex (VERX) stock rose following TD Cowen's initiation of coverage with a buy rating and $14 price target, implying 23.1% upside. The analyst believes the company can maintain double-digit revenue growth through fiscal 2028. Despite a 41% year-to-date decline, Vertex trades at a discount to historical valuations with strong Q1 2026 sales and free cash flow growth, though net revenue retention declined slightly.

Jefferies Financial reported mixed Q2 earnings with net earnings and revenue missing estimates, but achieved record investment banking revenue of $1.2 billion (up 58% YoY). While asset management revenue declined 46% due to market weakness and Point Bonita losses, the strong investment banking results suggest upcoming quarters for Goldman Sachs, Morgan Stanley, and JPMorgan Chase should be robust, as they won't face the same asset management headwinds.

SpaceX stock surged 20% on its IPO day and has continued climbing, but historical data suggests investors should wait before buying. Large IPOs that gain 26.5% in their first week typically only gain 3.5% over the following year. With SpaceX trading at a premium valuation (P/S of 130 vs. 10 for average tech stocks), waiting a year or so may yield better entry prices.